Reduced inflammation and CD4 loss in acute SHIV infection during oral pre-exposure prophylaxis

Journal of Infectious Diseases

Volumn 206, Issue 5, 2012, Pages 770-779

  Kersh, Ellen N ^a   Luo, Wei ^a   Zheng, Qi ^a   Adams, Debra R ^a   Hanson, Debra ^a   Youngpairoj, Ae S ^a   Cong, Mian Er ^a   Butler, Katherine ^a   Hendry, R Michael ^a   McNicholl, Janet M ^a   Heneine, Walid ^a   Garcia Lerma, J Gerardo ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GS 7340; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 15; INTERLEUKIN 18; PRODRUG; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LOSS; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; IMMUNOLOGICAL PARAMETERS; IN VIVO STUDY; INFECTION PREVENTION; INFLAMMATION; LYMPHOCYTE DEPLETION; MACACA; MALE; MEMORY T LYMPHOCYTE; NONHUMAN; PRE EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA; VIRUS LOAD;

ADENINE; ANIMALS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DEOXYCYTIDINE; DRUG COMBINATIONS; LONGITUDINAL STUDIES; MACACA MULATTA; MALE; ORGANOPHOSPHORUS COMPOUNDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; STATISTICS, NONPARAMETRIC; VIREMIA;

EID: 84864940074     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis422     Document Type: Article

References (45)

1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-74.
2. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New Engl J Med 2010; 363:2587-99.
3. Thigpen MC, Kebaabetswe PM, Smith DK, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study [abstract WELBC0]. In: 16th IAS Conference on HIV Pathogenesis, Treatment and Prevention (Rome).
4. Baeten J, Celum C, Team oboTPPS. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP study [abstract MOAX0106]. In: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. (Rome).
5. Roehr B. HIV prevention trial in women is abandoned after drugs show no impact on infection rates. BMJ 2011; 342:d2613.
6. Veronese F, Anton P, Fletcher CV, et al. Implications of HIV PrEP trials results. AIDS Res Hum Retrov 2011; 27:81-90.
7. Curtis KA, Kennedy MS, Luckay A, et al. Delayed maturation of antibody avidity but not seroconversion in rhesus macaques infected with simian HIV during oral pre-exposure prophylaxis. J Acquir Immun Defic Syndr 2011; 57:355-62.
8. Garcia-Lerma JG, Aung W, Cong ME, et al. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. J Virol 2011; 85:6610-7.
9. Garcia-Lerma JG, Cong ME, Mitchell J, et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med 2010; 2:14ra4.
10. Garcia-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008; 5:e28.
11. Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197:126-33. (Pubitemid 351263476)
12. Streeck H, Nixon DF. T cell immunity in acute HIV-1 infection. J Infect Dis 2010; 202(Suppl 2):S302-8.
13. Harouse JM, Gettie A, Eshetu T, et al. Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J Virol 2001; 75:1990-5. (Pubitemid 32110190)
14. Pahar B, Wang X, Dufour J, Lackner AA, Veazey RS. Virus-specific T cell responses in macaques acutely infected with SHIV(sf162p3). Virology 2007; 363:36-47. (Pubitemid 46678163)
15. Kersh EN, Luo W, Adams DR, et al. Short communication: no evidence of occult SHIV infection as demonstrated by CD8(+) cell depletion after chemoprophylaxis-induced protection from mucosal infection in rhesus macaques. AIDS Res Hum Retro 2008; 24: 543-6. (Pubitemid 351571040)
16. Kersh EN, Luo W, Adams DR, et al. Repeated rectal SHIVSF162P3 exposures do not consistently induce sustained T cell responses prior to systemic infection in the repeat-low dose preclinical macaque model. AIDS Res Hum Retro 2009; 25:905-17.
17. Liu J, Keele BF, Li H, et al. Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J Virol 2010; 84:10406-12.
18. Eberly MD, Kader M, Hassan W, et al. Increased IL-15 production is associated with higher susceptibility of memory CD4 T cells to simian immunodeficiency virus during acute infection. J Immunol 2009; 182:1439-48.
19. National Research Council. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press, 1996.
20. Yant LJ, Friedrich TC, Johnson RC, et al. The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol 2006; 80:5074-7.
21. Loffredo JT, Sidney J, Bean AT, et al. Two MHC class I molecules associated with elite control of immunodeficiency virus replication, Mamu-B*08 and HLA-B*2705, bind peptides with sequence similarity. J Immunol 2009; 182:7763-75.
22. Kirmaier A, Wu F, Newman RM, et al. TRIM5 suppresses crossspecies transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS Biol 2010; 8:e1000462.
23. Subbarao S, Otten RA, Ramos A, et al. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis 2006; 194:904-11. (Pubitemid 44454075)
24. Kersh EN, Adams DR, Youngpairoj AS, et al. T cell chemo-vaccination effects after repeated mucosal SHIV exposures and oral preexposure prophylaxis. PLoS One 2011; 6:e19295.
25. Hansen SG, Vieville C, Whizin N, et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009; 15:293-9.
26. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988; 44:1049-60. (Pubitemid 19026037)
27. Verhoeven D, Sankaran S, Silvey M, Dandekar S. Antiviral therapy during primary simian immunodeficiency virus infection fails to prevent acute loss of CD4+ T cells in gut mucosa but enhances their rapid restoration through central memory T cells. J Virol 2008; 82:4016-27. (Pubitemid 351521237)
28. Mehandru S, Dandekar S. Role of the gastrointestinal tract in establishing infection in primates and humans. Curr Opin HIV AIDS 2008; 3:22-7. (Pubitemid 351339925)
29. Owen RE, Heitman JW, Hirschkorn DF, et al. HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses. AIDS 2010; 24:1095-105.
30. Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999; 283:857-60.
31. Rosenwirth B, ten Haaft P, Bogers WM, et al. Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques. J Virol 2000; 74:1704-11. (Pubitemid 30434026)
32. van Rompay KK, Dailey PJ, Tarara RP, et al. Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virusinfected newborn rhesus macaques. J Virol 1999; 73:2947-55. (Pubitemid 29135683)
33. Watson A, McClure J, Ranchalis J, et al. Early postinfection antiviral treatment reduces viral load and prevents CD4+ cell decline in HIV type 2-infected macaques. AIDS Res Hum Retro 1997; 13: 1375-81. (Pubitemid 27460834)
34. Streeck H, Jessen H, Alter G, et al. Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J Infect Dis 2006; 194:734-9. (Pubitemid 44344119)
35. Hecht FM, Wang L, Collier A, et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 2006; 194:725-33. (Pubitemid 44344118)
36. Kubo M, Nishimura Y, Shingai M, et al. Initiation of antiretroviral therapy 48 hours after infection with simian immunodeficiency virus potently suppresses acute-phase viremia and blocks the massive loss of memory CD4+ T cells but fails to prevent disease. J Virol 2009; 83:7099-108.
37. Kader M, Hassan WM, Eberly M, et al. Antiretroviral therapy prior to acute viral replication preserves CD4 T cells in the periphery but not in rectal mucosa during acute simian immunodeficiency virus infection. J Virol 2008; 82:11467-71.
38. Lifson JD, Piatak M Jr, Cline AN, et al. Transient early postinoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge. J Med Primatol 2003; 32:201-10. (Pubitemid 37021245)
39. George MD, Reay E, Sankaran S, Dandekar S. Early antiretroviral therapy for simian immunodeficiency virus infection leads to mucosal CD4+ T-cell restoration and enhanced gene expression regulating mucosal repair and regeneration. J Virol 2005; 79: 2709-19. (Pubitemid 40270549)
40. Zheng Q, Ruone S, Switzer WM, Heneine W, Garcia-Lerma JG. Limited SHIV env diversification in macaques failing oral antiretroviral pre-exposure prophylaxis. Retrovirology 2012; 9:40.
41. Melchjorsen J, Risor MW, Sogaard OS, et al. Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12/IL-10 balance in human primary cells. J Acquir Immun Defic Syndr 2011; 57:265-75.
42. Cranage M, Sharpe S, Herrera C, et al. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local preexposure application of tenofovir gel. PLoS Med 2008; 5:e157; discussion e157.
43. Rolland M, Tovanabutra S, deCamp AC, et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med 2011; 17:366-71.
44. Mureithi MW, Poole D, Naranbhai V, et al. Preservation HIV-1-specific IFNgamma+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 Microbicide Trial. J Acquir Immun Defic Syndr 2012; 60:124-27.
45. Prada N, Davis B, Jean-Pierre P, et al. Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical course. J Acquir Immun Defic Syndr 2008; 49:117-22.